NEWS COMMENTARY

Smart ring company Oura seeks digital biomarkers for COVID-19 in research study with University of California, San Francisco

Published:
March 24, 2020
Services:
CPG More...
Priorities:
“Better-for-You” Transformation More...
Activities:
Research
by Danielle Bradnan
Truly disruptive

This research study to identify digital biomarkers comes on the heels of other studies based on smartphones and other wearables for early detection of other medical conditions, such as dementia and depression – as well as, in a notable study with Fitbit, the flu. This research is not only important for developing new tools to get a preliminary diagnosis in advance of testing for COVID-19 but also for advancing research for disease and population health management in the years to come after this crisis has passed. Clients should be looking for research partnerships with wearables startups to identify these biomarkers now as a way to  not only mitigate the current crisis but also continue future plays in healthcare.

For the original news article, click here .


Further Reading

Omada Health launches digital physical therapy tool as part of its chronic care management muskuloskeletal package

News Commentary | April 16, 2021

Omada Health has rolled out a product  offering that leverages last year's acquisition of Physera. The offering accomplishes two things. First, it helps further flesh out the ecosystem that Omada has built beyond just diabetes care, creating a "one‑stop shop" for customers needing multiple modes of ... Not part of subscription

Finnish food intelligence startup Veri raises funding for expansion, but pain points remain

News Commentary | June 23, 2021

The funding accelerates growth in the EU and enables expansion to the U.S. The solution includes an app and a wearable blood glucose tracker that has a tiny rubbery subcutaneous part and can accurately function for 14 days. The solution continuously measures blood sugar levels and provides real‑time... Not part of subscription

Blood diagnostic firm Tasso looks like a good opportunity as demand surges for at-home testing

News Commentary | December 22, 2021

Remote blood‑diagnostic‑device maker Tasso received a $100 million Series B cash infusion in response to a surge in demand for at‑home blood testing in the pandemic era. The investment round was led by RA Capital Management, and Tasso plans to use the funds primarily to scale the production of its ... Not part of subscription